Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer - Concepedia

Concepedia

Publication | Open Access

Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer

DOI Full Paper Access

42

Citations

38

References

2023

Year

Julie E. Bauman, Nabil F. Saba, Denise J. Roe, Jessica R. Bauman, John M. Kaczmar, Aarti Bhatia, Jameel Muzaffar, Ricklie Julian, Steven Wang, Shethal Bearelly,

Journal of Clinical Oncology

Abstract

The ficlatuzumab-cetuximab arm met significance criteria for PFS and warrants phase III development. HPV-negative HNSCC merits consideration as a selection criterion.

References

	Year	Citations

Page 1